The company’s quarterly update highlights a shift toward advancing its clinical pipeline, specifically focusing on recurrent C. difficile infections. Following recent discussions with the FDA, Acurx is aligning its strategy to utilize a single phase 3 study to support a future New Drug Application. Recent scientific data presented at the Anaerobe Society of the Americas congress suggests that ibezapolstat may offer superior biofilm disruption compared to current standard-of-care treatments, potentially allowing for better gut microbiome recovery in patients.

Financial results for the second quarter show a net loss of $2.3 million, or $0.53 per diluted share, reflecting increased R&D spending as the company scales manufacturing and consulting efforts for its upcoming trials. Total research and development expenses rose to $1.1 million for the quarter, up from $0.5 million in the same period last year. To support these operations, Acurx strengthened its balance sheet earlier this year through a registered direct offering that generated approximately $2.5 million in gross proceeds, ensuring the necessary capital to sustain its current exploratory clinical programs.